MedTrace Logo

Meloxicam for Pain Management After Total Joint Arthroplasty (TJA)

NCT05291598 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 223

Last updated 2024-08-14

Study results available
· View outcomes & findings →

Summary

The purpose of this project is to determine if a change in patient reported pain, nausea and vomiting after total knee and hip arthroplasty could be observed with the substitution of Intravenous meloxicam for ketorolac in the current established peri-operative pain protocol and if these changes lead to a decrease in opioid consumption (in morphine equivalents).

Conditions

  • Total Knee Replacement
  • Total Hip Replacement

Interventions

DRUG

IV meloxicam

Participants will be administered meloxicam 30 mg IV push pre-operatively.

DRUG

Ketorolac

Participants will be treated with ketorolac 15 mg IV push intra-operatively, followed by 15 mg IV push every 6 hours scheduled for 2 doses.

Sponsors & Collaborators

  • University of Miami

    lead OTHER

Principal Investigators

  • Victor H Hernandez, MD · University of Miami

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-05-01
Primary Completion
2023-05-01
Completion
2023-05-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05291598 on ClinicalTrials.gov